SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 17, 2020

CLEARSIGN TECHNOLOGIES CORPORATION

(Exact name of registrant as specified in Charter)

12870 Interurban Avenue South

Seattle, Washington 98168

(Address of Principal Executive Offices)

206-673-4848

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On June 18, 2020, ClearSign Technologies Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the decision of Dr. Lon E. Bell not to stand for election as a director at the Company’s 2020 annual meeting of shareholders (the “Annual Meeting”), which was held on June 17, 2020, the Company no longer meets the requirements of Listing Rule 5605(b)(1) (Majority Independent Board) and Listing Rule 5605(c)(2) (Audit Committee Composition). However, consistent with Listing Rules 5605(b)(1)(A) and 5605(c)(4), Nasdaq has provided the Company a cure period in order to regain compliance as follows:

The Company intends to undertake a search for an independent director and to appoint that person to the Board of Directors within the cure period.

As noted above, on June 17, 2020, the Company held its Annual Meeting. A total of 21,882,468 shares of common stock, constituting a quorum, were represented in person or by proxies at the Annual Meeting. The following are the voting results on each matter submitted to the shareholders. The proposals below are described in detail in the Company’s proxy statement, which was filed with the Securities and Exchange Commission on April 27, 2020.

Proposal 1. Each of the following nominees was elected to serve as a director until the election and qualification of his or her successor.

Proposal 2. The shareholders approved, on an advisory basis, Gumbiner Savett Inc. as the Company’s independent registered public accounting firm for the year ended December 31, 2020.

Proposal 3. The shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers.

Proposal 4. The shareholders approved one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies in the absence of a quorum.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 22, 2020